Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees.
Any global strategy for controlling the human immunodeficiency virus (HIV) epidemic is likely to rely heavily on immunization of infants and children. Given the well-documented differences in children's responses to traditional vaccines, we initiated this study to extend our findings on DNA vaccination of adult chimpanzees to immunologically immature infant chimpanzees. Our findings were consistent with our previous work in adults as we observed that the DNA vaccines used here were both well tolerated and immunogenic within weeks of the initial vaccination.
Bagarazzi
M L
ML
University of Pennsylvania School of Medicine, Department of Pediatrics, Children's Hospital of Philadelphia, 19104, USA.
Boyer
J D
JD
Javadian
M A
MA
Chattergoon
M
M
Dang
K
K
Kim
G
G
Shah
J
J
Wang
B
B
Weiner
D B
DB
D016915:AIDS Vaccines / Q000009:adverse effects; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D000818:Animals; D000917:Antibody Formation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015483:HIV Antibodies / Q000096:biosynthesis*; D015699:HIV Envelope Protein gp120; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007111:Immunity, Cellular; D007273:Injections, Intramuscular; D002679:Pan troglodytes; D019444:Vaccines, DNA; D014621:Vagina
D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D019444:Vaccines, DNA